Premium
Effect of Troglitazone on Steady‐State Pharmacokinetics of Digoxin
Author(s) -
Loi ChoMing,
Knowlton Philip W.,
Stern Ralph,
Randinitis Edward J.,
Vassos Artemios B.,
Koup Jeffrey R.,
Sedman Allen J.
Publication year - 1998
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1998.tb04408.x
Subject(s) - digoxin , pharmacokinetics , troglitazone , oral administration , medicine , urine , steady state (chemistry) , radioimmunoassay , cmax , pharmacology , endocrinology , chemistry , heart failure , peroxisome , receptor
Twelve healthy subjects participated in a study to determine the effect of multiple doses of troglitazone on the steady‐state pharmacokinetics of digoxin. Subjects received digoxin 0.25 mg orally once daily on days 1 through 20 and 400 mg of troglitazone orally once daily on days 11 through 20. Serial plasma samples and 24‐hour urine samples collected before and after the doses on days 10 and 20 were analyzed for digoxin using a radioimmunoassay method. Eleven subjects completed the study. Administration of multiple oral doses of digoxin and troglitazone was well tolerated. Mean values for maximum concentration (C max ), time to C max (t max ), and area under the concentration—time curve from 0 to 24 hours (AUC 0–24 ) of digoxin on day 10 were similar to those on day 20. Mean day 10 digoxin values for minimum concentration (C min ), apparent oral clearance (Cl/F), total urinary excretion from 0 to 24 hours (Ae 0–24 ), and renal clearance (Cl r ) were also similar to corresponding values on day 20. Thus, concomitant administration of multiple‐dose troglitazone does not alter the steady‐state pharmacokinetics of digoxin.